Poly-l-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy

Minigo, Gabriela; Scholzen, Anja; Tang, Choon Kit; Hanley, Jennifer C; Kalkanidis, Martha; Pietersz, Geoffrey A.; Apostolopoulos, Vasso; Plebanski, Magdalena

doi:10.1016/j.vaccine.2006.09.086

Cited by 135 publications

(83 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 DNA adsorbed onto the surface of cationic microparticles and nanoparticles has previously been reported to enhance DNA delivery. 24,25 However, in our study, colloidal stabilization of AgNP-PEG is likely to have occurred because of the presence of van der Waals forces between the negatively charged oxygen groups present in the molecular structure of PEG ( Figure 1A) and the positively charged groups that surround the surfaces of the inert AgNPs. 26 Overall, binding of DNA to cationic AgNPs enables substantial protection of the DNA for potential application in gene therapy and gene engineering.…”

mentioning

confidence: 61%

Gene expression profiles in primary duodenal chick cells following transfection with avian influenza virus H5 DNA plasmid encapsulated in silver nanoparticles

Jazayeri¹,

Ideris²,

Shameli³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:In order to develop a systemically administered safe and effective nonviral gene delivery system against avian influenza virus (AIV) that induced cytokine expression, the hemagglutinin (H5) gene of AIV, A/Ck/Malaysia/5858/04 (H5N1) and green fluorescent protein were cloned into a coexpression vector pIRES (pIREGFP-H5) and formulated using green synthesis of silver nanoparticles (AgNPs) with poly(ethylene glycol) and transfected into primary duodenal cells taken from 18-day-old specific-pathogen-free chick embryos. The AgNPs were prepared using moderated temperature and characterized for particle size, surface charge, ultraviolet-visible spectra, DNA loading, and stability. AgNPs and AgNPpIREGFP-H5 were prepared in the size range of 13.9 nm and 25 nm with a positive charge of +78 ± 0.6 mV and +40 ± 6.2 mV, respectively. AgNPs with a positive surface charge could encapsulate pIREGFP-H5 efficiently. The ultraviolet-visible spectra for AgNP-pIREGFP-H5 treated with DNase I showed that the AgNPs were able to encapsulate pIREGFP-H5 efficiently. Polymerase chain reaction showed that AgNP-pIREGFP-H5 entered into primary duodenal cells rapidly, as early as one hour after transfection. Green fluorescent protein expression was observed after 36 hours, peaked at 48 hours, and remained stable for up to 60 hours. In addition, green fluorescent protein expression generally increased with increasing DNA concentration and time. Cells were transfected using Lipocurax in vitro transfection reagent as a positive control. A multiplex quantitative mRNA gene expression assay in the transfected primary duodenal cells via the transfection reagent and AgNPs with pIREGFP-H5 revealed expression of interleukin (IL)-18, IL-15, and IL-12β.

show abstract

mentioning

confidence: 61%

Gene expression profiles in primary duodenal chick cells following transfection with avian influenza virus H5 DNA plasmid encapsulated in silver nanoparticles

Jazayeri¹,

Ideris²,

Shameli³

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that the size of the nanoparticles being used as the DNA delivery platforms can have a significant effect on the DNA vaccine efficacy. 5,18,25,43 The use of particular delivery platforms as a novel method of delivering a payload of proteins and/or plasmid DNA immunogens to induce a positive immune response is a research area that is currently receiving a great deal of interest. The characteristics of both micro-and nanosized particles can have a significant impact on the overall performance of the delivery system.…”

Section: Resultsmentioning

confidence: 99%

“…4,[28][29][30]39,45,46 However, the application of nanoparticles as delivery platforms with DNA vaccines as payloads is only at the exploratory stage. 33,43 In this present preliminary study, the potential application of using a biodegradable, nontoxic copolymer (pHEMA nanoparticles) as a delivery platform to carry pCAG-HAk plasmid DNA has been investigated. In the past, pHEMA has been used in drug delivery systems; 26,31 however, to date, it appears that this study is the first to use pHEMA nanoparticles as an adjuvant in DNA vaccination.…”

Section: Figurementioning

confidence: 99%

Ultrasonic synthetic technique to manufacture a pHEMA nanopolymeric-based vaccine against the H6N2 avian influenza virus: a preliminary investigation

Poinern¹,

Le²,

Shan³

et al. 2011

IJN

View full text Add to dashboard Cite

Abstract:This preliminary study investigated the use of poly (2-hydroxyethyl methacrylate) (pHEMA) nanoparticles for the delivery of the deoxyribonucleic acid (DNA) vaccine pCAGHAk, which expresses the full length hemagglutinin (HA) gene of the avian influenza A/Eurasian coot/Western Australian/2727/1979 (H6N2) virus with a Kozak sequence which is in the form of a pCAGGS vector. The loaded and unloaded nanoparticles were characterized using fieldemission scanning electron microscopy. Further characterizations of the nanoparticles were made using atomic force microscopy and dynamic light scattering, which was used to investigate particle size distributions. This preliminary study suggests that using 100 µg of pHEMA nanoparticles as a nanocarrier/adjuvant produced a reduction in virus shedding and improved the immune response to the DNA vaccine pCAG-HAk.

show abstract

“…From several studies, it emerged that nanoparticles in the viral size range (around 40 nm), rather than bacterial-sized microparticles ( > 1000 nm), are superior DNA vaccine carriers, capable of inducing high levels of CD8+ T cells as well as antibodies against the pDNA-encoded antigen [62,86]. Binding of pDNA to carboxylated polystyrene particles via a poly-l-lysine (PLL) linker offering cationic charges that mediate electrostatic binding to the negatively charged DNA strongly enhanced the uptake of DNA by bone-marrow-derived DCs in vitro, and the ability of the DNA to induce potent cellular and humoral immune responses to the encoded antigen in vivo [86].…”

Section: Particulate Carriersmentioning

confidence: 99%

Applications of immunochemistry in human health: advances in vaccinology and antibody design (IUPAC Technical Report)

Klein

Templeton

Schwenk

2014

Pure and Applied Chemistry

View full text Add to dashboard Cite

This report discusses the history and mechanisms of vaccination of humans as well as the engineering of therapeutic antibodies. Deeper understanding of the molecular interactions involved in both acquired and innate immunity is allowing sophistication in design of modified and even synthetic vaccines. Recombinant DNA technologies are facilitating development of DNA-based vaccines, for example, with the recognition that unmethylated CpG sequences in plasmid DNA will target Toll-like receptors on antigen-presenting cells. Formulations of DNA vaccines with increased immunogenicity include engineering into plasmids with "genetic adjuvant" capability, incorporation into polymeric or magnetic nanoparticles, and formulation with cationic polymers and other polymeric and non-polymeric coatings. Newer methods of delivery, such as particle bombardment, DNA tattooing, electroporation, and magnetic delivery, are also improving the effectiveness of DNA vaccines. RNA-based vaccines and reverse vaccinology based on gene sequencing and bioinformatic approaches are also considered. Structural vaccinology is an approach in which the detailed molecular structure of viral epitopes is used to design synthetic antigenic peptides. Virus-like particles are being designed for vaccine deliveries that are based on structures of viral capsid proteins and other synthetic lipopeptide building blocks. A new generation of adjuvants is being developed to further enhance immunogenicity, based on squalene and other oil-water emulsions, saponins, muramyl dipeptide, immunostimulatory oligonucleotides, Toll-like receptor ligands, and lymphotoxins. Finally, current trends in engineering of therapeutic antibodies including improvements of antigen-binding properties, pharmacokinetic and pharmaceutical properties, and reduction of immunogenicity are discussed. Taken together, understanding the chemistry of vaccine design, delivery and immunostimulation, and knowledge of the techniques of antibody design are allowing targeted development for the treatment of chronic disorders characterized by continuing activation of the immune system, such as autoimmune disorders, cancer, or allergies that have long been refractory to conventional approaches.

show abstract

Poly-l-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy

Cited by 135 publications

References 56 publications

Gene expression profiles in primary duodenal chick cells following transfection with avian influenza virus H5 DNA plasmid encapsulated in silver nanoparticles

Gene expression profiles in primary duodenal chick cells following transfection with avian influenza virus H5 DNA plasmid encapsulated in silver nanoparticles

Ultrasonic synthetic technique to manufacture a pHEMA nanopolymeric-based vaccine against the H6N2 avian influenza virus: a preliminary investigation

Applications of immunochemistry in human health: advances in vaccinology and antibody design (IUPAC Technical Report)

Contact Info

Product

Resources

About